In healthy volunteers, ABT-089, a partial agonist of the neuronal receptors α4β2 and α6β2, can reverse the cognitive deficit brought on by hyoscine however, in patients with mild-to-moderate AD enrolled in Phase 2 RCT were receiving treatment with a steady acetylcholinesterase inhibitor found no efficacy (Greco et al., 2009). This evidence concerns the gene ACHE and Alzheimer disease.